Zevra Therapeutics (ZVRA) legal chief sells 1,794 shares under 10b5-1 plan

Rhea-AI Filing Summary

Zevra Therapeutics Chief Legal & Compliance officer Rahsaan Thompson reported an open-market sale of 1,794 shares of common stock at $11.30 per share. After this transaction, he directly holds 48,125 shares. The sale was executed pursuant to a Rule 10b5-1(c) trading plan adopted on 01-08-2026, indicating it was pre-scheduled rather than a discretionary trade.

Insider Trade Summary 10b5-1

Net Seller: 1,794 shares ($20,272)

Net Sell 1 txn

Insider Thompson Rahsaan

Role Chief Legal & Compliance

Sold 1,794 shs ($20K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,794	$11.30	$20K

Holdings After Transaction: Common Stock — 48,125 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 1,794 shares Sale price: $11.30 per share Shares held after sale: 48,125 shares

3 metrics

Shares sold 1,794 shares Open-market sale of common stock

Sale price $11.30 per share Price for the 1,794 sold shares

Shares held after sale 48,125 shares Direct ownership following the transaction

Key Terms

Rule 10b5-1(c) plan, open-market sale, Common Stock

3 terms

Rule 10b5-1(c) plan regulatory

"Adoption date of referenced 10b5-1(c) plan is: 01-08-2026"

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thompson Rahsaan

(Last) (First) (Middle)

C/O ZEVRA THERAPEUTICS, INC.

101 FEDERAL STREET

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ZEVRA THERAPEUTICS, INC. [ ZVRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal & Compliance

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/11/2026		S(1)		1,794	D	$11.3	48,125	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Adoption date of referenced 10b5-1(c) plan is: 01-08-2026

Remarks:

	/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Rahsaan W. Thompson	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Zevra Therapeutics (ZVRA) report for Rahsaan Thompson?

Zevra Therapeutics reported that Chief Legal & Compliance officer Rahsaan Thompson sold 1,794 shares of common stock in an open-market transaction at $11.30 per share. Following the sale, he directly holds 48,125 shares, as disclosed in the Form 4 filing.

At what price were the ZVRA shares sold in the latest Form 4 filing?

The reported shares of Zevra Therapeutics common stock were sold at an average price of $11.30 per share. This price applies to the 1,794 shares sold in the open-market transaction disclosed for Chief Legal & Compliance officer Rahsaan Thompson.

How many Zevra Therapeutics (ZVRA) shares does Rahsaan Thompson hold after the sale?

After the reported transaction, Rahsaan Thompson directly holds 48,125 shares of Zevra Therapeutics common stock. This figure reflects his ownership position immediately following the open-market sale of 1,794 shares reported in the Form 4.

Was the Zevra Therapeutics insider sale made under a Rule 10b5-1 trading plan?

Yes. The Form 4 footnote states the sale was made under a Rule 10b5-1(c) trading plan adopted on 01-08-2026. Such plans allow pre-scheduled trades, helping separate routine portfolio management from discretionary insider decisions.

What role does Rahsaan Thompson hold at Zevra Therapeutics (ZVRA)?

Rahsaan Thompson serves as Chief Legal & Compliance officer at Zevra Therapeutics. His position is disclosed in the Form 4, which reports his open-market sale of 1,794 shares of the company’s common stock and his remaining 48,125 directly held shares.